Foamix Pharmaceuticals Fourth Quarter and Fiscal Year 2015 Financial Results Conference Call & Webcast Scheduled for Thursday, March 3

REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will announce fourth quarter and fiscal year 2015 ended December 31, 2015 financial results and host a conference call and webcast on Thursday, March 3.

Conference Call & Webcast
Thursday, March 3, 2016 @ 8am Eastern Time

Toll Free:888-329-8862
International: 719-325-2361
Conference ID:1046957
Replays, through March 17th
Conference ID:1046957

About Foamix Pharmaceuticals Ltd.

Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX102 for the treatment of impetigo, FMX 103 for the treatment of rosacea, and FDX104, our doxycycline foam for the management of acne-like rash, induced by EGFRI anticancer drugs.

In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare, Merz, Allergan and Prestium.

Contact: Ilan Hadar, CFO Foamix Pharmaceuticals Ltd. +972-8-9316233 US Investor Relations Michael Rice LifeSci Advisors, LLC 646-597-6979

Source:Foamix, Ltd.